title: Effects of Rut-bpy (Cis-[Ru(bpy)2(SO3)(NO)]PF 6), a novel nitric oxide donor, in L-NAME-induced hypertension in rats.
abstract: OBJECTIVE
  To evaluate the effect of Rut-bpy (Cis-[Ru(bpy)2(SO3)(NO)]PF 6), a novel nitric oxide donor in Nω-nitro-L-arginine methyl ester (L-NAME)-induced hypertensive rats.
  
  
  METHODS
  Twenty-four male Wistar rats were randomly assigned to four groups (n=6), named according to the treatment applied (G1-Saline, G2-Rut-bpy, G3-L-NAME and G4-L-NAME+Rut-bpy). L-NAME (30 mg/Kg) was injected intraperitoneally 30 minutes before the administration of Rut-bpy (100 mg/Kg). Mean abdominal aorta arterial blood pressure (MAP) was continuously monitored.
  
  
  RESULTS
  Mean arterial blood pressure (MAP) in G3 rats rose progressively, reaching 147±16 mmHg compared with 100±19 mm Hg in G1 rats (p<0.05). In G4 rats, treated with L-NAME+Rut-bpy, MAP reached 149+11 mm Hg while in G2 rats, treated with Rut-bpy, MAP values were 106±11 mm Hg. In G1 rats these values decreased progressively reaching 87+14 mm Hg after 30 minutes. An important finding was the maintenance of the MAP throughout the experiment in G2 rats.
  
  
  CONCLUSIONS
  Rut-bpy does not decrease the MAP in L-Name induced hypertensive rats. However, when it is used in anesthetized hypotensive rats a stable blood pressure is obtained.
authors.affiliation: Department of Surgery, Federal University of Ceara, Fortaleza-CE, Brazil.
authors.forename: Marcio Wilker Soares
authors.initials: MW
authors.lastname: Campelo
authors.forename: Ana Paula Bomfim Soares
authors.initials: AP
authors.lastname: Campelo
authors.forename: Luiz Gonzaga de França
authors.initials: LG
authors.lastname: Lopes
authors.forename: Armenio Aguiar Dos
authors.initials: AA
authors.lastname: Santos
authors.forename: Sergio Botelho
authors.initials: SB
authors.lastname: Guimarães
authors.forename: Paulo Roberto Leitão de
authors.initials: PR
authors.lastname: Vasconcelos
mesh_terms: D000758:Anesthesia; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects* / Q000502:physiology; D056831:Coordination Complexes / Q000494:pharmacology*; D004195:Disease Models, Animal; D006973:Hypertension / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D019331:NG-Nitroarginine Methyl Ester; D009569:Nitric Oxide / Q000096:biosynthesis; D020030:Nitric Oxide Donors / Q000494:pharmacology*; D009942:Organometallic Compounds / Q000378:metabolism / Q000494:pharmacology*; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D012428:Ruthenium / Q000378:metabolism / Q000494:pharmacology*; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000378:metabolism / Q000494:pharmacology*
chemical_list: D056831:Coordination Complexes; D020030:Nitric Oxide Donors; D009942:Organometallic Compounds; D014665:Vasodilator Agents; D009569:Nitric Oxide; D012428:Ruthenium; D019331:NG-Nitroarginine Methyl Ester